key: cord-0899286-enpes34c
authors: Harita, Shimpei; Hamaguchi, Jun; Shimizu, Keiki; Honda, Hitoshi
title: Respiratory extracorporeal membrane oxygenation and central-line–associated bloodstream infection: Experience at a tertiary-care center during the coronavirus disease 2019 (COVID-19) pandemic
date: 2021-08-02
journal: Infect Control Hosp Epidemiol
DOI: 10.1017/ice.2021.331
sha: f9a31967b5fa10e82dc4bf3b4011cfe6d5c3c732
doc_id: 899286
cord_uid: enpes34c

nan

This retrospective study was conducted from December 2013 to the end of February 2021 in 28-bed intensive care units at Tokyo Metropolitan Tama Medical Center, a 790-bed, public, tertiarycare center in Tokyo, Japan. The study center began respiratory ECMO placement in December 2013. The center has been registered with the extracorporeal life support organization (ELSO) since 2015, 5 and 10-20 respiratory ECMO placements are performed there annually.

Patients who received respiratory ECMO during the study period were enrolled for analysis. Their demographic data, indication for ECMO placement, ECMO device days (called ECMO days), duration of ICU hospitalization, in-hospital mortality at the index hospitalization, the number of ECMO-CLABSI events, and causative pathogens were extracted from the electronic medical records. ECMO-CLABSI patients were required to have a laboratory-confirmed bloodstream infection that was not secondary to an infection at another body site. The definitions of CLABSI, ECMO days, and the ECMO device utilization ratio (DUR) from the National Healthcare Safety Network (NHSN) were used for ECMO-CLABSI. 6 The incidence density of ECMO-CLABSI and the ECMO-DUR were calculated. The Institutional Review Board of the Tokyo Metropolitan Tama Medical Center approved this study.

In total, 97 patients received respiratory ECMO placement, and the cumulative ECMO-days were 1,138. The in-hospital mortality rate was 38.1% (37 of 97), the median respiratory ECMO-days per patient was 8.0 days (range, 1-55), and the overall ECMO-DUR was 0.023. All the patients with ECMO were concurrently fitted with a central venous catheter and arterial catheter during ECMO use.

In total, ECMO-CLABSI developed in 12 patients, and the cumulative incidence density of ECMO-CLABSI during the entire study period was 10.54 per 1,000 ECMO days. Figure 1 shows the trends in the ECMO-CLABSI incidence and the ECMO-DUR. After February 2020, when the study center began admitting patients with COVID-19, both the ECMO-DUR and ECMO-CLABSI incidence density increased noticeably in comparison with the preceding period The ECMO-DUR was 0.018-0.061, with a rate ratio of 3.29 (95% confidence interval [CI], 2.89-3.72). The ECMO-CLABSI incidence density was 10.11-11.53 per 1.000 ECMO days, with an incidence ratio of 1.14 (95% CI, 0.16-3.42). The most common causative pathogens in ECMO-CLABSI were Candida spp (3 of 12) followed by Staphylococcus spp (2 of 12). In-hospital mortality was higher in patients with ECMO-CLABSI than in those without ECMO-CLBSI: 75.0% (9 of 12) versus 32.9% (28 of 85).

When the outcomes of the patients with COVID-19 on ECMO were compared with those without COVID-19 (Supplementary  Table 1 online), the former tended to be more obese (body mass index >25 km/m 2 ). Although the difference was statistically nonsignificant, more ECMO-CLABSI cases were observed among patients with COVID-19. The incidence density was 16.19 per 1,000 ECMO days among patients with COVID-19 versus 8.98 per 1,000 ECMO days among those without COVID-19, for an incidence ratio of 1.80 (95% CI, 0.26-5.41).

In this study, we examined trends in respiratory ECMO use over 7 years at a tertiary-care center in Japan. The overall incidence density of ECMO-CLABSI was 10.54 per 1,000 ECMO days, which is in line with other observational studies. 3, 4 Respiratory ECMO use has increased since the COVID-19 pandemic began, and increasing incidence density of ECMO-CLABSI has also been observed.

The clear increase in the incidence density of ECMO-CLABSI following the COVID-19 outbreak in the present study reflects the findings of a previous study in which an increase in the incidence of healthcare-associated infections, including CLABSI, occurred during the COVID-19 pandemic. 7,8 Supplementary Table 1 (online) shows that the proportion of patients with BMI >25 kg/m 2 was higher among those with COVID-19 while on ECMO. Although central venous catheterization in the femoral vein should be avoided in obese patients, 9 respiratory ECMO catheterization is frequently performed using the femoral vein. Dressing failure, local contamination, and local bacterial overgrowth create suboptimal conditions for the catheterization site. Moreover, prolonged catheterization, which can also contribute to ECMO-CLABSI development, has been observed in patients with COVID-19. Given the increased use of ECMO during the COVID-19 pandemic, an evidence-based approach is urgently needed to prevent ECMO-CLABSI.

This study has several limitations. Because it was conducted at a single tertiary-care center, its findings may not apply to other institutions. Because all patients with ECMO were fitted with a central venous catheter and an arterial catheter, distinguishing ECMO-CLABSI from other catheter-related BSI was challenging. Moreover, ECMO-CLABSI may not have caused the death of the patients with ECMO. Because relatively few patients were enrolled, further studies enrolling a larger cohort are needed to verify these findings. Although there is a consensus on indications for ECMO placement, some variation in the ECMO procedure in the present study may have affected the results.

In the present study, we determined the incidence of ECMO-CLABSI at a tertiary-care center in Japan. Since the COVID-19 pandemic began, demand for ECMO use has been increasing, and patients with COVID-19 requiring ECMO placement may be at risk of developing ECMO-CLABSI. Further studies enrolling a larger patient population with ECMO placement in the context of COVID-19 care are needed to clarify the ECMO-CLABSI risk in patients with COVID-19.

Extracorporeal Life Support Corporation (ELSO) webisite

Bloodstream infection in patients on venovenous extracorporeal membrane oxygenation for respiratory failure

To be a CLABSI or not to be a CLABSI-that is the question: the epidemiology of BSI in a large ECMO population

Epidemiology of blood stream infection in adult extracorporeal membrane oxygenation patients: a cohort study

Extracorporeal Life Support Corporation (ELSO) website

Bloodstream infection event (central-line-associated bloodstream infection and non-centralline-associated bloodstream infection). Centers for Disease Control Fig. 1. Trends in extracorporeal membrane oxygenation (ECMO) central-line-associated bloodstream infection and the ECMO device utilization ratio. and Prevention website

Coronavirus disease 2019 (COVID-19) pandemic, central-line-associated bloodstream infection (CLABSI), and catheter-associated urinary tract infection (CAUTI): the urgent need to refocus on hardwiring prevention efforts

Impact of COVID-19 pandemic on central-line-associated bloodstream infections during the early months of 2020, National Healthcare Safety Network

Strategies to prevent central-lineassociated bloodstream infections in acute-care hospitals

Acknowledgments. We thank the staff of the Department of Critical Care at Tokyo Metropolitan Tama Medical Center for managing the patients. We are also grateful to Mr. James R. Valera for his assistance with editing this manuscript.Financial support. No financial support was provided relevant to this article.

Supplementary material. To view supplementary material for this article, please visit https://doi.org/10.1017/ice.2021.331